Naval Daver

Naval Daver is a clinical investigator specializing in high-risk MDS and AML who has led pioneering studies of venetoclax-based combinations in these diseases. He contributed to early clinical trials establishing azacitidine plus venetoclax activity in both AML and MDS, informing subsequent regulatory approvals. His research program extends to IDH1/2 inhibitors, FLT3-targeted combinations, and immunotherapy approaches for myeloid malignancies. He has a particular focus on genomically defined patient subgroups and rational biomarker-driven treatment selection.